“Continuum Biologics’ PIPE-791 Advances with Johnson & Johnson Partnership in Initial Public Offering (IPO)”

- Continuum Biologics, the originator of PIPE-791 (a small molecule drug), has gained attention for its IPO queue entry.
- PIPE-791 is a Lysophosphatidic acid receptor Edg-2 antagonist and LPAR1 antagonist.
- The drug targets therapeutic areas such as multiple sclerosis, demyelinating diseases, and neuroinflammation.
- As of April 6, 2024, PIPE-791 is in Phase 1 clinical trials for multiple sclerosis in the US, with preclinical studies ongoing for demyelinating diseases and neuroinflammation.
- Johnson & Johnson has partnered with Continuum Biologics, although specific details about their collaboration are not provided in this search result.